Aquestive Therapeutics, Inc. — Form 8-K Summary
Filing date: September 25, 2026; reporting event date: September 23, 2026. The filing was submitted under Item 7.01, Regulation FD Disclosure, and relates to an investor presentation for meetings with institutional investors, analysts, and other parties.
Business Context
Aquestive Therapeutics furnished its corporate investor presentation dated September 23, 2026, as Exhibit 99.1. The presentation is available on the company’s investor-relations website, subject to the company’s right to discontinue availability. The presentation may be amended or updated through a subsequent filing or other means.
Financial Metrics and Liquidity
The provided Form 8-K text does not include revenue, profit or loss, cash flow, margins, debt, liquidity, operating results, or other quantitative financial metrics. The attached investor presentation was referenced but its contents were not provided in the filing text supplied.
Material Changes Versus Prior Period
No material changes versus a prior comparable period are disclosed in the provided filing text.
Guidance, Outlook, Risks, and Unusual Items
- No financial guidance, forecast, or formal outlook is provided in the filing text.
- No new risk factors, contingencies, legal matters, or unusual accounting items are disclosed.
- The investor presentation may be amended or updated, and its availability on the company’s website may be discontinued.
- The Item 7.01 information, including Exhibit 99.1, is furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Review Exhibit 99.1 to assess the company’s current strategy, pipeline, commercial plans, financial information, and forward-looking statements.
- Verify whether subsequent filings update or amend the September 23, 2026 investor presentation.
- Review the company’s latest periodic reports for current revenue, cash balance, cash runway, debt, operating losses, and liquidity.
- Consider the customary risks and uncertainties associated with forward-looking statements in the investor presentation.